Yoichi Yoshida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yoichi Yoshida has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Eiichi Kobayashi
Department of Neurosurgery, National Hospital Organization Chiba Medical Center, Chiba, Japan
4 shared publications- Takaki Hiwasa
Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
4 shared publications Yasuo Iwadate
Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
4 shared publications- Hao Wang
The First Affiliated Hospital of Jinan University, China
3 shared publications - Hideaki Shimada
Department of Clinical Oncology, Graduate School of Medicine, Toho University, Tokyo, Japan
3 shared publications - Hirotaka Takizawa
Port Square Kashiwado Clinic, Kashiwado Memorial Foundation, Chiba 260-0025, Japan
3 shared publications
Latest Publications
- Open Access
- 7 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2465
A Latent Autoantibody Axis Associated with Vascular Vulnerability in Ischemic Stroke: Integrated Statistical and Machine-Learning Analysis
Ischemic stroke remains a major cause of mortality and long-term disability worldwide, and improved strategies for identifying individuals at elevated vascular risk are needed. Serum autoantibodies have emerged as potential biomarkers reflecting vascular injury and immune activation; however, their integrative biological significance and incremental predictive value beyond established clinical risk factors remain unclear. We analyzed 833 participants, including patients with acute ischemic stroke (AIS) or transient ischemic attack (TIA) and healthy controls. Serum levels of anti-PDCD11 antibody (Ab), anti-DNAJC2 antibody, and anti-PAI-1 (SERPINE1) antibody were quantified, and multivariable logistic regression and machine-learning (ML) models (logistic regression and random forest) were constructed using clinical variables with and without antibody markers. Model performance was evaluated using cross-validation, bootstrap-derived confidence intervals, calibration metrics, and reclassification indices. Model interpretability analyses, principal component analysis (PCA), unsupervised clustering, and propensity score matching were performed to explore latent biological structures. Clinical-only models demonstrated excellent discrimination (bootstrap Area Under the Curve (AUC) 0.917 for random forest and 0.919 for logistic regression). The addition of antibody markers yielded similar performance (AUC 0.913 and 0.923, respectively) without evidence of meaningful improvement in reclassification. However, SHapley Additive exPlanations (SHAP) analysis identified antibody markers as influential contributors following major clinical risk factors. PCA revealed a dominant antibody component explaining approximately 79% of the variance, which remained independently associated with stroke after age adjustment. Unsupervised clustering further identified a high-risk subgroup characterized by consistently elevated antibody levels. These findings support the presence of a latent antibody axis associated with vascular vulnerability. Although antibody markers did not substantially enhance global predictive performance, they captured integrated biological signals reflecting cumulative vascular and immunological stress. Autoantibody profiling may complement conventional risk assessment by improving biological characterization of stroke susceptibility. Prospective validation in independent cohorts is required prior to clinical implementation.
- 7 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2465
Open AccessA Latent Autoantibody Axis Associated with Vascular Vulnerability in Ischemic Stroke: Integrated Statistical and Machine-Learning Analysis
Ischemic stroke remains a major cause of mortality and long-term disability worldwide, and improved strategies for identifying individuals at elevated vascular risk are needed. Serum autoantibodies have emerged as potential biomarkers reflecting vascular injury and immune activation; however, their integrative biological significance and incremental predictive value beyond established clinical risk factors remain unclear. We analyzed 833 participants, including patients with acute ischemic stroke (AIS) or transient ischemic attack (TIA) and healthy controls. Serum levels of anti-PDCD11 antibody (Ab), anti-DNAJC2 antibody, and anti-PAI-1 (SERPINE1) antibody were quantified, and multivariable logistic regression and machine-learning (ML) models (logistic regression and random forest) were constructed using clinical variables with and without antibody markers. Model performance was evaluated using cross-validation, bootstrap-derived confidence intervals, calibration metrics, and reclassification indices. Model interpretability analyses, principal component analysis (PCA), unsupervised clustering, and propensity score matching were performed to explore latent biological structures. Clinical-only models demonstrated excellent discrimination (bootstrap Area Under the Curve (AUC) 0.917 for random forest and 0.919 for logistic regression). The addition of antibody markers yielded similar performance (AUC 0.913 and 0.923, respectively) without evidence of meaningful improvement in reclassification. However, SHapley Additive exPlanations (SHAP) analysis identified antibody markers as influential contributors following major clinical risk factors. PCA revealed a dominant antibody component explaining approximately 79% of the variance, which remained independently associated with stroke after age adjustment. Unsupervised clustering further identified a high-risk subgroup characterized by consistently elevated antibody levels. These findings support the presence of a latent antibody axis associated with vascular vulnerability. Although antibody markers did not substantially enhance global predictive performance, they captured integrated biological signals reflecting cumulative vascular and immunological stress. Autoantibody profiling may complement conventional risk assessment by improving biological characterization of stroke susceptibility. Prospective validation in independent cohorts is required prior to clinical implementation.
- Open Access
- 17 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (10) , 5470
Stage-Specific Alteration and Prognostic Relationship of Serum Fumarate Hydratase Autoantibodies in Gastric Cancer
The relationship between energy production and cancer is attracting attention. This study aimed to investigate the clinicopathological significance of fumarate hydratase (FH), a tricarboxylic acid cycle enzyme, in gastric cancer using autoantibodies as biomarkers. The study analyzed 116 patients who underwent gastric cancer surgery and 96 healthy controls. Preoperative serum FH autoantibody (s-FH-Ab) titers were analyzed using an immunosorbent assay with an amplified luminescent proximity homogeneous assay. Receiver operating characteristic analysis was used to determine the cutoff s-FH-Ab titer. Clinicopathological factors and prognosis were compared between the high and low s-FH-Ab groups. The s-FH-Ab levels were significantly higher in the gastric cancer group than in the control group (p = 0.01). Levels were elevated even in patients with stage I gastric cancer compared with healthy controls (p = 0.02). A low s-FH-Ab level was significantly associated with distant metastasis (p = 0.01), peritoneal dissemination (p < 0.05), and poor overall survival (p < 0.01). Multivariate analysis revealed that low s-FH-Ab levels were an independent risk factor for poor prognosis (p < 0.01). Therefore, s-FH-Ab levels may be a useful biomarker for early diagnosis and the prediction of prognosis in patients with gastric cancer.
- 17 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (10) , 5470
Open AccessStage-Specific Alteration and Prognostic Relationship of Serum Fumarate Hydratase Autoantibodies in Gastric Cancer
The relationship between energy production and cancer is attracting attention. This study aimed to investigate the clinicopathological significance of fumarate hydratase (FH), a tricarboxylic acid cycle enzyme, in gastric cancer using autoantibodies as biomarkers. The study analyzed 116 patients who underwent gastric cancer surgery and 96 healthy controls. Preoperative serum FH autoantibody (s-FH-Ab) titers were analyzed using an immunosorbent assay with an amplified luminescent proximity homogeneous assay. Receiver operating characteristic analysis was used to determine the cutoff s-FH-Ab titer. Clinicopathological factors and prognosis were compared between the high and low s-FH-Ab groups. The s-FH-Ab levels were significantly higher in the gastric cancer group than in the control group (p = 0.01). Levels were elevated even in patients with stage I gastric cancer compared with healthy controls (p = 0.02). A low s-FH-Ab level was significantly associated with distant metastasis (p = 0.01), peritoneal dissemination (p < 0.05), and poor overall survival (p < 0.01). Multivariate analysis revealed that low s-FH-Ab levels were an independent risk factor for poor prognosis (p < 0.01). Therefore, s-FH-Ab levels may be a useful biomarker for early diagnosis and the prediction of prognosis in patients with gastric cancer.
- Open Access
- 30 April 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (9) , 4935
JMJD6 Autoantibodies as a Potential Biomarker for Inflammation-Related Diseases
Inflammation is closely associated with cerebrovascular diseases, cardiovascular diseases, diabetes, and cancers, and it is accompanied by the development of autoantibodies in the early stage of inflammation-related diseases. Hence, it is meaningful to discover novel antibody biomarkers targeting inflammation-related diseases. In this study, Jumonji C-domain-containing 6 (JMJD6) was identified by the serological identification of antigens through recombinant cDNA expression cloning. In particular, JMJD6 is an antigen recognized in serum IgG from patients with unstable angina pectoris (a cardiovascular disease). Then, the serum antibody levels were examined using an amplified luminescent proximity homogeneous assay-linked immunosorbent assay and a purified recombinant JMJD6 protein as an antigen. We observed elevated levels of serum anti-JMJD6 antibodies (s-JMJD6-Abs) in patients with inflammation-related diseases such as ischemic stroke, acute myocardial infarction (AMI), diabetes mellitus (DM), and cancers (including esophageal cancer, EC; gastric cancer; lung cancer; and mammary cancer), compared with the levels in healthy donors. The s-JMJD6-Ab levels were closely associated with some inflammation indicators, such as C-reactive protein and intima–media thickness (an atherosclerosis index). A better postoperative survival status of patients with EC was observed in the JMJD6-Ab-positive group than in the negative group. An immunohistochemical analysis showed that JMJD6 was highly expressed in the inflamed mucosa of esophageal tissues, esophageal carcinoma tissues, and atherosclerotic plaques. Hence, JMJD6 autoantibodies may reflect inflammation, thereby serving as a potential biomarker for diagnosing specific inflammation-related diseases, including stroke, AMI, DM, and cancers, and for prediction of the prognosis in patients with EC.
- 30 April 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (9) , 4935
Open AccessJMJD6 Autoantibodies as a Potential Biomarker for Inflammation-Related Diseases
Inflammation is closely associated with cerebrovascular diseases, cardiovascular diseases, diabetes, and cancers, and it is accompanied by the development of autoantibodies in the early stage of inflammation-related diseases. Hence, it is meaningful to discover novel antibody biomarkers targeting inflammation-related diseases. In this study, Jumonji C-domain-containing 6 (JMJD6) was identified by the serological identification of antigens through recombinant cDNA expression cloning. In particular, JMJD6 is an antigen recognized in serum IgG from patients with unstable angina pectoris (a cardiovascular disease). Then, the serum antibody levels were examined using an amplified luminescent proximity homogeneous assay-linked immunosorbent assay and a purified recombinant JMJD6 protein as an antigen. We observed elevated levels of serum anti-JMJD6 antibodies (s-JMJD6-Abs) in patients with inflammation-related diseases such as ischemic stroke, acute myocardial infarction (AMI), diabetes mellitus (DM), and cancers (including esophageal cancer, EC; gastric cancer; lung cancer; and mammary cancer), compared with the levels in healthy donors. The s-JMJD6-Ab levels were closely associated with some inflammation indicators, such as C-reactive protein and intima–media thickness (an atherosclerosis index). A better postoperative survival status of patients with EC was observed in the JMJD6-Ab-positive group than in the negative group. An immunohistochemical analysis showed that JMJD6 was highly expressed in the inflamed mucosa of esophageal tissues, esophageal carcinoma tissues, and atherosclerotic plaques. Hence, JMJD6 autoantibodies may reflect inflammation, thereby serving as a potential biomarker for diagnosing specific inflammation-related diseases, including stroke, AMI, DM, and cancers, and for prediction of the prognosis in patients with EC.
- Open Access
- 17 January 2024
- Published by MDPI AG in Preprints.org
JMJD6 Autoantibodies as a Potential Biomarker for Atherosclerosis-Related Diseases
Atherosclerosis is associated with vascular diseases, diabetes, and cancers. The Jumonji C-domain-containing 6 (JMJD6) gene plays an important role in diverse biological processes. In addition, autoantibodies are reportedly useful in the early diagnosis and treatment of many diseases. Here, JMJD6 was identified by serological identification of antigens by recombinant cDNA expression cloning as an antigen recognized by serum IgG from patients with unstable angina pectoris. Then, we performed amplified luminescent proximity homogeneous assay-linked immunosorbent assay using purified recombinant antigens and found elevated levels of serum anti-JMJD6 antibodies (s-JMJD6-Abs) in patients with atherosclerosis-related diseases including ischemic stroke, acute myocardial infarction (AMI), diabetes mellitus (DM), and cancers including esophageal cancer (EC), gastric cancer, lung cancer, and mammary cancer, compared with those in healthy donors. The s-JMJD6-Ab levels were closely associated with hypertension, habitual smoking, and the intima-media thickness, an atherosclerosis index. The better postoperative survival status was shown in patients with EC from the JMJD6-Ab-positive group than the negative group, especially from JMJD6-Ab-positive/PD-L1-negative group and JMJD6-Ab-positive/p53-Ab-negative group than JMJD6-Ab-negative/PD-L1-positive group and JMJD6-Ab-negative/p53-Ab-positive group, respectively. Hence, JMJD6 autoantibodies may reflect atherosclerosis severity, thereby a potential biomarker for atherosclerosis-related diseases including ischemic stroke, AMI, DM, and cancers and for predicting EC prognosis.
- 17 January 2024
- Published by MDPI AG in Preprints.org
Open AccessJMJD6 Autoantibodies as a Potential Biomarker for Atherosclerosis-Related Diseases
Atherosclerosis is associated with vascular diseases, diabetes, and cancers. The Jumonji C-domain-containing 6 (JMJD6) gene plays an important role in diverse biological processes. In addition, autoantibodies are reportedly useful in the early diagnosis and treatment of many diseases. Here, JMJD6 was identified by serological identification of antigens by recombinant cDNA expression cloning as an antigen recognized by serum IgG from patients with unstable angina pectoris. Then, we performed amplified luminescent proximity homogeneous assay-linked immunosorbent assay using purified recombinant antigens and found elevated levels of serum anti-JMJD6 antibodies (s-JMJD6-Abs) in patients with atherosclerosis-related diseases including ischemic stroke, acute myocardial infarction (AMI), diabetes mellitus (DM), and cancers including esophageal cancer (EC), gastric cancer, lung cancer, and mammary cancer, compared with those in healthy donors. The s-JMJD6-Ab levels were closely associated with hypertension, habitual smoking, and the intima-media thickness, an atherosclerosis index. The better postoperative survival status was shown in patients with EC from the JMJD6-Ab-positive group than the negative group, especially from JMJD6-Ab-positive/PD-L1-negative group and JMJD6-Ab-positive/p53-Ab-negative group than JMJD6-Ab-negative/PD-L1-positive group and JMJD6-Ab-negative/p53-Ab-positive group, respectively. Hence, JMJD6 autoantibodies may reflect atherosclerosis severity, thereby a potential biomarker for atherosclerosis-related diseases including ischemic stroke, AMI, DM, and cancers and for predicting EC prognosis.
- Open Access
- 25 September 2022
- Published by Elsevier in Radiology Case Reports
- Vol. 17 (12) , 4470-4477
Ruptured bilateral middle cerebral artery aneurysms diagnosed based on cerebral vasospasm-associated ischemic symptoms: A case report
- 25 September 2022
- Published by Elsevier in Radiology Case Reports
- Vol. 17 (12) , 4470-4477
Open AccessRuptured bilateral middle cerebral artery aneurysms diagnosed based on cerebral vasospasm-associated ischemic symptoms: A case report
- Open Access
- 1 January 2022
- Published by The Japanese Society for Neuroendovascular Therapy in Journal of Neuroendovascular Therapy
- Vol. 16 (12) , 600-605
Carotid Artery Stenting for Patients with Radiation-Induced Carotid Artery Stenosis
Objective: In radiation-induced carotid artery stenosis (RIS), morphological characteristics, such as bilateral and long lesion distances and in-stent stenosis, have been reported as common after carotid artery stenting (CAS). Here, we present 25 cases at our hospital wherein CAS was performed for RIS and compare the morphological characteristics and the safety of the treatment with cases of atherosclerotic carotid artery stenosis (AS).Methods: Twenty-five lesions from 21 patients underwent CAS for RIS at our hospital between March 2002 and July 2020. The procedure was performed at a mean of 10.0 ± 5.2 years after radiation therapy with 60–72 Gy, with a median follow-up of 45 months. We retrospectively selected consecutive patients with AS with comparable follow-up times from the beginning of the study as controls. We compared the patients’ background, stenosis findings including plaque MRI, perioperative period, and postoperative course.Results: All patients in both groups completed the procedure, and the median follow-up time for the RIS and AS groups was 45 and 40 months, respectively (p = 0.1479). Patients in the RIS group had a lower mean age (69.9 ± 6.9 vs. 75.3 ± 7.04, p = 0.0075), a higher stenosis rate (79.1 ± 8.7% vs. 68.6 ± 11.7%, p = 0.0032), and longer stenosis greater than one vertebra (long lesions) (10 vs. 1, p = 0.0046) compared with the patients in the AS group. Although there was no significant difference in outcomes between the two groups, restenosis tended to be more common in the RIS group. Plaque MRI was characterized by a significantly higher T2WI signal (p = 0.0381) in the RIS group, which was attributable to the fact that a necrotic core has been reported commonly in the plaque tissue of RIS.Conclusion: RIS has a high likelihood of restenosis both morphologically and in terms of plaque characteristics. Thus, close follow-up is crucial.
- 1 January 2022
- Published by The Japanese Society for Neuroendovascular Therapy in Journal of Neuroendovascular Therapy
- Vol. 16 (12) , 600-605
Open AccessCarotid Artery Stenting for Patients with Radiation-Induced Carotid Artery Stenosis
Objective: In radiation-induced carotid artery stenosis (RIS), morphological characteristics, such as bilateral and long lesion distances and in-stent stenosis, have been reported as common after carotid artery stenting (CAS). Here, we present 25 cases at our hospital wherein CAS was performed for RIS and compare the morphological characteristics and the safety of the treatment with cases of atherosclerotic carotid artery stenosis (AS).Methods: Twenty-five lesions from 21 patients underwent CAS for RIS at our hospital between March 2002 and July 2020. The procedure was performed at a mean of 10.0 ± 5.2 years after radiation therapy with 60–72 Gy, with a median follow-up of 45 months. We retrospectively selected consecutive patients with AS with comparable follow-up times from the beginning of the study as controls. We compared the patients’ background, stenosis findings including plaque MRI, perioperative period, and postoperative course.Results: All patients in both groups completed the procedure, and the median follow-up time for the RIS and AS groups was 45 and 40 months, respectively (p = 0.1479). Patients in the RIS group had a lower mean age (69.9 ± 6.9 vs. 75.3 ± 7.04, p = 0.0075), a higher stenosis rate (79.1 ± 8.7% vs. 68.6 ± 11.7%, p = 0.0032), and longer stenosis greater than one vertebra (long lesions) (10 vs. 1, p = 0.0046) compared with the patients in the AS group. Although there was no significant difference in outcomes between the two groups, restenosis tended to be more common in the RIS group. Plaque MRI was characterized by a significantly higher T2WI signal (p = 0.0381) in the RIS group, which was attributable to the fact that a necrotic core has been reported commonly in the plaque tissue of RIS.Conclusion: RIS has a high likelihood of restenosis both morphologically and in terms of plaque characteristics. Thus, close follow-up is crucial.
- Open Access
- 1 January 2022
- Published by The Japanese Society for Neuroendovascular Therapy in Journal of Neuroendovascular Therapy
- Vol. 16 (2) , 106-115
Two Patients with Reversible Cerebral Vasoconstriction after Carotid Artery Stenting
Objective: We herein report two cases of transient cerebral vasoconstriction after carotid artery stenting (CAS). Case Presentation: An 81-year-old man presented with asymptomatic severe stenosis in the right carotid artery accompanied by a slight reduction in cerebrovascular reactivity. CAS was performed, but the patient had a generalized seizure because of transient cerebral ischemia caused by intolerance to carotid artery occlusion with balloon protection. Confusion and left hemiparesis persisted. DSA suggested cerebral ischemia due to vasoconstriction as the cause of these prolonged symptoms. A 66-year-old man presented with asymptomatic severe stenosis in the right carotid artery with slight hypoperfusion. CAS was performed. The patient developed left hemispatial neglect, dysarthria, and left hemiparesis 12 hours after the procedure. DSA revealed cerebral vasoconstriction in the responsible territory. The conditions of both patients improved within several days with medical treatment and they were discharged without neurological deficits. Conclusion: The cases presented herein show that transient ischemic complications caused by cerebral vasoconstriction may develop after CAS.
- 1 January 2022
- Published by The Japanese Society for Neuroendovascular Therapy in Journal of Neuroendovascular Therapy
- Vol. 16 (2) , 106-115
Open AccessTwo Patients with Reversible Cerebral Vasoconstriction after Carotid Artery Stenting
Objective: We herein report two cases of transient cerebral vasoconstriction after carotid artery stenting (CAS). Case Presentation: An 81-year-old man presented with asymptomatic severe stenosis in the right carotid artery accompanied by a slight reduction in cerebrovascular reactivity. CAS was performed, but the patient had a generalized seizure because of transient cerebral ischemia caused by intolerance to carotid artery occlusion with balloon protection. Confusion and left hemiparesis persisted. DSA suggested cerebral ischemia due to vasoconstriction as the cause of these prolonged symptoms. A 66-year-old man presented with asymptomatic severe stenosis in the right carotid artery with slight hypoperfusion. CAS was performed. The patient developed left hemispatial neglect, dysarthria, and left hemiparesis 12 hours after the procedure. DSA revealed cerebral vasoconstriction in the responsible territory. The conditions of both patients improved within several days with medical treatment and they were discharged without neurological deficits. Conclusion: The cases presented herein show that transient ischemic complications caused by cerebral vasoconstriction may develop after CAS.
- Open Access
- 1 January 2018
- Published by Japan Neurosurgical Society in Neurologia medico-chirurgica
- Vol. 58 (7) , 303-310
Elevation of Autoantibody in Patients with Ischemic Stroke
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 January 2018
- Published by Japan Neurosurgical Society in Neurologia medico-chirurgica
- Vol. 58 (7) , 303-310
Open AccessElevation of Autoantibody in Patients with Ischemic Stroke
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies